Literature DB >> 14615744

Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.

Kristi L Bengtson1, Michael A Skinner, Russell E Ware.   

Abstract

Thrombocytopenia with life-threatening hemorrhage in childhood immune thrombocytopenic purpura is rare, but effective therapeutic options are limited for the patient with bleeding. We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14615744     DOI： 10.1067/S0022-3476(03)00446-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  4 in total

Review 1.  Treatment with rituximab in benign and malignant hematologic disorders in children.

Authors:  Lisa B Giulino; James B Bussel; Ellis J Neufeld
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

2.  Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.

Authors:  Carolyn M Bennett; Zora R Rogers; Daniel D Kinnamon; James B Bussel; Donald H Mahoney; Thomas C Abshire; Hadi Sawaf; Theodore B Moore; Mignon L Loh; Bertil E Glader; Maggie C McCarthy; Brigitta U Mueller; Thomas A Olson; Adonis N Lorenzana; William C Mentzer; George R Buchanan; Henry A Feldman; Ellis J Neufeld
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

3.  Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.

Authors:  Emilia Parodi; Bruno Nobili; Silverio Perrotta; Sofia Maria Rosaria Matarese; Giovanna Russo; Maria Licciardello; Marco Zecca; Franco Locatelli; Simone Cesaro; Gianni Bisogno; Paola Giordano; Domenico De Mattia; Ugo Ramenghia
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

Review 4.  Rituximab for children with immune thrombocytopenia: a systematic review.

Authors:  Yi Liang; Lingli Zhang; Ju Gao; Die Hu; Yuan Ai
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.